Wells Fargo & Company Cuts NovoCure (NASDAQ:NVCR) Price Target to $49.00

NovoCure (NASDAQ:NVCR – Get Free Report) had its price target decreased by equities researchers at Wells Fargo & Company from $102.00 to $49.00 in a report issued on Tuesday, MarketBeat.com reports. The brokerage currently has an “overweight” rating on the medical equipment provider’s stock. Wells Fargo & Company‘s price target indicates a potential upside of […]

Related Keywords

United States ,China ,Japan ,Optune Lua ,Piper Sandler ,Marshall Wace ,Blackrock Inc ,Wells Fargo Company ,Norges Bank ,Capital International Investors ,Novocure Company Profile ,Pricet Rowe Associates Inc ,Get Free Report ,Wells Fargo ,International Investors ,Cure Limited ,Middle East ,Novocure Daily ,Novocure ,Nasdaq Nvcr ,Nvcr ,Medical ,Lower Price Target ,